Quantcast
  • E-mail
  • Print
  • Comment
  • Font Size
  • Digg
  • del.icio.us
  • Discuss article

U.S. FDA warns Pfizer over ad for antibiotic drug

Posted on: Tuesday, 26 July 2005, 11:29 CDT

WASHINGTON (Reuters) - U.S. regulators warned Pfizer Inc. about "misleading promotion" of its antibiotic drug Zyvox in a professional journal, according to a letter released on Tuesday.

The advertisement does not include information about Zyvox's risks, implies it is superior without supporting evidence, and claims it can treat more infections than for which it was approved, the U.S. Food and Drug Administration letter said.

The agency called on the drugmaker to halt the advertisement and take the extra step of sending out new, more accurate promotions.

"Because the violations ... are serious, we request, further, that your submission include a comprehensive plan of action to disseminate truthful, nonmisleading and complete corrective messages," the letter said.

The company has until August 3 to respond to the warning, and Pfizer spokesman Daniel Watts said the drugmaker would send the agency a letter next week.

"Pfizer will immediately take steps to cease distribution of the professional advertisement cited by the FDA," he said.

Zyvox, which comes as an injection, tablet and liquid, is used to treat skin infections. It also treats two types of pneumonia, one caused by methicillin-resistant Staphylococcus aureus (MRSA) and another caused by Streptococcus pneumoniae.

Patients using the drug can experience blood disorders like anemia and a build-up of lactic acid in the cells and blood -- but those risks were not included in the ad, the FDA said.

The agency also said it "implies that Zyvox is superior" for treating nonsocomial pneumonia, compared to vancomycin, which Eli Lilly and Co. sells under the brand name Vancocin.

A headline in the ad -- "MRSA meets its match" -- also implies the drug "is useful in all infections caused by MRSA, a broader range of conditions than is approved," the FDA said.

Shares of the New York-based drugmaker were off 3 cents, or less than 1 percent, at $26.38 in midday trading on the New York Stock Exchange.


Source: REUTERS

More News in this Category


Related Articles



Rating: 2.4 / 5 (9 votes)
Rate this article:
1/52/53/54/55/5

User Comments (0)

Comment on this article

Your Name
Text from the image
Comment
max 1200 chars
* All fields are required